GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia.
Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong JS, Ip HF, van der Zee MD, Bartels M, Day FR, Fontanillas P, Elson SL; 23andMe Research Team; de Wit H, Davis LK, MacKillop J; Substance Use Disorders Working Group of the Psychiatric Genomics Consortium; International Cannabis Consortium; Derringer JL, Branje SJT, Hartman CA, Heath AC, van Lier PAC, Madden PAF, Mägi R, Meeus W, Montgomery GW, Oldehinkel AJ, Pausova Z, Ramos-Quiroga JA, Paus T, Ribases M, Kaprio J, Boks MPM, Bell JT, Spector TD, Gelernter J, Boomsma DI, Martin NG, MacGregor S, Perry JRB, Palmer AA, Posthuma D, Munafò MR, Gillespie NA, Derks EM, Vink JM.
Pasman JA, et al. Among authors: davis lk.
Nat Neurosci. 2018 Sep;21(9):1161-1170. doi: 10.1038/s41593-018-0206-1. Epub 2018 Aug 27.
Nat Neurosci. 2018.
PMID: 30150663
Free PMC article.